CHEN-HUA LIUCHUN-JEN LIUJIA-HORNG KAO2021-09-042021-09-0420071320-5358https://www.scopus.com/inward/record.uri?eid=2-s2.0-33846969903&doi=10.1111%2fj.1440-1797.2006.00703.x&partnerID=40&md5=081222348cf30523476e922b42674771https://scholars.lib.ntu.edu.tw/handle/123456789/582168[SDGs]SDG3interferon; peginterferon; peginterferon alpha2a; peginterferon alpha2b; ribavirin; acute graft rejection; antiviral activity; combination chemotherapy; dialysis; drug clearance; drug efficacy; drug safety; editorial; graft survival; hepatitis B; hepatitis C; human; kidney disease; kidney transplantation; liver cell carcinoma; liver cirrhosis; low drug dose; monotherapy; priority journal; survival rate; viremia; Antiviral Agents; Hepatitis C, Chronic; Humans; Interferons; Renal Dialysiseditorial10.1111/j.1440-1797.2006.00703.x172956542-s2.0-33846969903